Global Orthobiologics Market

Orthobiologics Market Size, Share, Growth Analysis, By Product(Viscosupplementation Products, Demineralized Bone Matrices, Synthetic Orthobiologics, Bone Morphogenic Protein), By Application(Osteoarthritis and Degenerative Arthritis, Spinal Fusion, Soft-Tissue Injuries, Fracture Recovery), By End User(Hospitals, Orthopedic Clinics, & Ambulatory Care Centers), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35D2070 | Region: Global | Published Date: September, 2024
Pages: 157 | Tables: 92 | Figures: 76

Orthobiologics Market Insights

Global Orthobiologics Market size was valued at USD 6.1 billion in 2022 and is poised to grow from USD 6.43 billion in 2023 to USD 9.87 billion by 2031, growing at a CAGR of 5.5% during the forecast period (2024-2031).

Orthobiologics comprises a wide range of products that improve healing of musculoskeletal conditions and injuries. This comprises stem cells, bone grafts, PRP (plasma-rich-platelet), and several other regenerative treatments. The global orthobiologics market is considerably impacted by factors like increasing developments and advances in regenerative medicine therapies, growing senior population, and growing incidences of orthopedic procedures. Nonetheless, a few restraints hampering the growth of the orthobiologics market include stringent approval processes, lack of standardization, and costly surgeries and treatments. Still, the market is anticipated to witness substantial growth over the estimated period owing to opportunities like expanding applications of orthobiologics, rising research and developments, and growing inclination towards personalized medicine.

US Orthobiologics Market is poised to grow at a sustainable CAGR for the next forecast year.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Orthobiologics Market size was valued at USD 6.1 billion in 2022 and is poised to grow from USD 6.43 billion in 2023 to USD 9.87 billion by 2031, growing at a CAGR of 5.5% during the forecast period (2024-2031).

The global orthobiologics market is a competitive and speedy evolving market driven by the prominent market players. The leading companies like Johnson & Johnson, Medtronic, and Stryker are holding major market share with a broader range of products like stem cells and several growth factors. There is an increasing emphasis on obedience with stringent regulatory norms that affect market entry and timelines of product development for simplified approvals. Speedy advances in technology like surgeries, strategic collaborations, and heavy investments and expenditures on R&D define the competitive landscape. 'Medtronic plc', 'Stryker Corporation ', 'Globus Medical, Inc. ', 'Orthofix International N.V. ', 'RTI Surgical, Inc. ', 'Kuros Biosciences Ltd. ', 'Bioventus LLC ', 'Nuvasive, Inc. ', 'Seaspine Holdings Corporation ', 'Arthrex, Inc. ', 'Xtant Medical Holdings, Inc. ', 'Sanofi S.A. ', 'Smith & Nephew plc ', 'Integra LifeSciences Holdings Corporation ', 'Anika Therapeutics, Inc. ', 'Alphatec Spine, Inc. ', 'Orthocell Ltd. ', 'MiMedx Group, Inc. ', 'Orthofix Medical Inc. ', 'Bone Therapeutics SA'

Modernized technologies and R&D are majorly impacting the growth of the orthobiologics market, innovations in PRP, stem cell therapies, and several other associated techniques are increasing the accessibility, availability, and efficacy of orthobiologics, thus impacting the market growth. Moreover, current research and trials are resulting in the emergence of novel treatment modalities and products. This improves the healing process and overall recovery. 

Growing Prominence of PRP Treatment: Platelet-Rich Plasma or PRP is gaining significant prominence for its application in joint pain, soft tissue injuries, and post-surgical recovery. Hence, it is majorly gaining popularity in regenerative applications. Moreover, the growing number of efforts and initiatives are being imposed to standardize preparation of PRP and administration policies to improve reproducibility and efficacy.  

Geographically, North America dominated the market in 2023 and is expected to lead over the forecast period owing to the presence of improved healthcare infrastructure, growing cases of musculoskeletal issues, and strong research and growing number of research and developments. North America brags about its developed healthcare infrastructure with easy access to superior technologies and well-trained professionals. Regional growth is also impacted by the rising number of sports patients that report sports injuries and osteoarthritis issues. This majorly demands improved and innovative treatments. Furthermore, increasing amount of research and development fuels modernizations in orthobiologics, resulting in the emergence of novel therapies. The key players profiled in the region include Amgen Inc., Medtronic, Zimmer Biomet, Stryker Corporation, Amedica Corporation, Bone Therapeutics, and more.    

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Orthobiologics Market

Report ID: SQMIG35D2070

$5,300
BUY NOW GET FREE SAMPLE